Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy

Tyrosine kinase inhibitors (TKIs) such as imatinib (IM) are key drugs for treatment of chronic myeloid leukemia (CML). Development of drug resistance to TKIs due to BCR-ABL mutation, especially T315I mutation, poses a major challenge in the clinical treatment of CML. The purpose of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yiqing, Zeng, Peiting, Xiao, Jie, Huang, Peng, Liu, Panpan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021256/
https://www.ncbi.nlm.nih.gov/pubmed/35443725
http://dx.doi.org/10.1038/s41420-022-00991-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021256/
https://www.ncbi.nlm.nih.gov/pubmed/35443725
http://dx.doi.org/10.1038/s41420-022-00991-w

Ejemplares similares